Template:Medications and dosages used in hormone therapy for transgender women
Appearance
Medication | Brand name | Type | Route | Dosage[b] |
---|---|---|---|---|
Estradiol | Various | Estrogen | Oral | 2–10 mg/day |
Various | Estrogen | Sublingual | 1–8 mg/day | |
Climara[c] | Estrogen | TD patch | 25–400 μg/day | |
Divigel[c] | Estrogen | TD gel | 0.5–5 mg/day | |
Various | Estrogen | SC implant | 50–200 mg every 6–24 mos | |
Estradiol valerate | Progynova | Estrogen | Oral | 2–10 mg/day |
Progynova | Estrogen | Sublingual | 1–8 mg/day | |
Delestrogen[c] | Estrogen | IM, SC | 2–10 mg/wk or 5–20 mg every 2 wks | |
Estradiol cypionate | Depo-Estradiol | Estrogen | IM, SC | 2–10 mg/wk or 5–20 mg every 2 wks |
Estradiol dipropionate | Agofollin | Estrogen | IM, SC | 2–10 mg/wk or 5–20 mg every 2 wks |
Estradiol benzoate | Progynon-B | Estrogen | IM, SC | 0.5–1.5 mg every 2–3 days |
Estriol | Ovestin[c] | Estrogen | Oral | 4–6 mg/day |
Spironolactone | Aldactone | Antiandrogen | Oral | 100–400 mg/day |
Cyproterone acetate | Androcur | Antiandrogen; Progestogen |
Oral | 5–100 mg/day |
Androcur Depot | IM | 300 mg/month | ||
Bicalutamide | Casodex | Antiandrogen | Oral | 25–50 mg/day |
Enzalutamide | Xtandi | Antiandrogen | Oral | 160 mg/day |
GnRH analogue | Various | GnRH modulator | Various | Variable |
Elagolix | Orilissa | GnRH antagonist | Oral | 150 mg/day or 200 mg twice daily |
Finasteride | Propecia | 5αR inhibitor | Oral | 1–5 mg/day |
Dutasteride | Avodart | 5αR inhibitor | Oral | 0.25–0.5 mg/day |
Progesterone | Prometrium[c] | Progestogen | Oral | 100–400 mg/day |
Medroxyprogesterone acetate | Provera | Progestogen | Oral | 2.5–40 mg/day |
Depo-Provera | Progestogen | IM | 150 mg every 3 mos | |
Depo-SubQ Provera 104 | Progestogen | SC | 104 mg every 3 mos | |
Hydroxyprogesterone caproate | Proluton | Progestogen | IM | 250 mg/wk |
Dydrogesterone | Duphaston | Progestogen | Oral | 20 mg/day |
Drospirenone | Slynd | Progestogen | Oral | 3 mg/day |
Domperidone[d] | Motilium | Prolactin releaser | Oral | 30–80 mg/day[e] |
|
Template documentation
See also
- Template:Estrogen dosages for menopausal hormone therapy
- Template:Estrogen dosages for breast and prostate cancer
- Template:Medications and dosages used in hormone therapy for transgender men
References
- ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017). "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline". The Journal of Clinical Endocrinology and Metabolism. 102 (11): 3869–3903. doi:10.1210/jc.2017-01658. PMID 28945902. S2CID 3726467.
- ^ Deutsch M (17 June 2016). "Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People" (PDF) (2nd ed.). University of California, San Francisco: Center of Excellence for Transgender Health. p. 28.
- ^ Dahl M, Feldman JL, Goldberg J, Jaberi A, Bockting WO, Knudson G (2015). "Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines" (PDF). Vancouver Coastal Health. Retrieved 15 August 2018.
- ^ Bourns A (2015). "Guidelines and Protocols for Comprehensive Primary Care for Trans Clients" (PDF). Sherbourne Health Centre. Retrieved 15 August 2018.
- ^ Wylie K, Barrett J, Besser M, Bouman WP, Bridgman M, Clayton A, Green R, Hamilton M, Hines M, Ivbijaro G, Khoosal D, Lawrence A, Lenihan P, Loewenthal D, Ralph D, Reed T, Stevens J, Terry T, Thom B, Thornton J, Walsh D, Ward D, Coleman E, Di Ceglie D, Martin E, McGarry P, Messenger A, Reid R, Sethi S, Sutcliffe P, Wilson D, Carr S, Davies D, Dean T, Ellis M, Ferguson B, Skinner D, Williams V, Brechin S, Lucey J, Rathbone M (2014). "Good Practice Guidelines for the Assessment and Treatment of Adults with Gender Dysphoria" (PDF). Sexual and Relationship Therapy. 29 (2): 154–214. doi:10.1080/14681994.2014.883353. ISSN 1468-1994. S2CID 144632597. Archived from the original (PDF) on 2018-09-02.
- ^ Wesp LM, Deutsch MB (March 2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". The Psychiatric Clinics of North America. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID 28159148.
- ^ Unger CA (December 2016). "Hormone therapy for transgender patients". Translational Andrology and Urology. 5 (6): 877–884. doi:10.21037/tau.2016.09.04. PMC 5182227. PMID 28078219.
- ^ Randolph JF (December 2018). "Gender-Affirming Hormone Therapy for Transgender Females". Clinical Obstetrics and Gynecology. 61 (4): 705–721. doi:10.1097/GRF.0000000000000396. PMID 30256230. S2CID 52821192.
- ^ Nakatsuka M (May 2010). "Endocrine treatment of transsexuals: assessment of cardiovascular risk factors". Expert Review of Endocrinology & Metabolism. 5 (3): 319–322. doi:10.1586/eem.10.18. PMID 30861686. S2CID 73253356.
- ^ Fishman SL, Paliou M, Poretsky L, Hembree WC (2019). "Endocrine Care of Transgender Adults". Transgender Medicine. Contemporary Endocrinology. pp. 143–163. doi:10.1007/978-3-030-05683-4_8. ISBN 978-3-030-05682-7. ISSN 2523-3785. S2CID 86772102.
- ^ Winkler-Crepaz K, Müller A, Böttcher B, Wildt L (2017). "Hormonbehandlung bei Transgenderpatienten" [Hormone treatment of transgender patients]. Gynäkologische Endokrinologie. 15 (1): 39–42. doi:10.1007/s10304-016-0116-9. ISSN 1610-2894. S2CID 12270365.
- ^ Urdl W (2009). "Behandlungsgrundsätze bei Transsexualität" [Therapeutic principles in transsexualism]. Gynäkologische Endokrinologie. 7 (3): 153–160. doi:10.1007/s10304-009-0314-9. ISSN 1610-2894. S2CID 8001811.
- ^ Gooren LJ (March 2011). "Clinical practice. Care of transsexual persons". The New England Journal of Medicine. 364 (13): 1251–1257. doi:10.1056/NEJMcp1008161. PMID 21449788.
- ^ Barrett J (29 September 2017). Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management. CRC Press. pp. 216–. ISBN 978-1-315-34513-0.
- ^ Trombetta C, Liguori G, Bertolotto M (3 March 2015). Management of Gender Dysphoria: A Multidisciplinary Approach. Springer. pp. 85–. ISBN 978-88-470-5696-1.
- ^ Fabris B, Bernardi S, Trombetta C (March 2015). "Cross-sex hormone therapy for gender dysphoria". Journal of Endocrinological Investigation. 38 (3): 269–282. doi:10.1007/s40618-014-0186-2. hdl:11368/2831597. PMID 25403429. S2CID 207503049.
- ^ Eckstrand K, Ehrenfeld JM (17 February 2016). Lesbian, Gay, Bisexual, and Transgender Healthcare: A Clinical Guide to Preventive, Primary, and Specialist Care. Springer. pp. 357–. ISBN 978-3-319-19752-4.
- ^ Tangpricha V, den Heijer M (April 2017). "Oestrogen and anti-androgen therapy for transgender women". The Lancet. Diabetes & Endocrinology. 5 (4): 291–300. doi:10.1016/S2213-8587(16)30319-9. PMC 5366074. PMID 27916515.
- ^ Coxon J, Seal L (2018). "Hormone management of trans women". Trends in Urology & Men's Health. 9 (6): 10–14. doi:10.1002/tre.663. ISSN 2044-3730. S2CID 222189278.
- ^ Gooren LJ, Giltay EJ, Bunck MC (January 2008). "Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience". The Journal of Clinical Endocrinology and Metabolism. 93 (1): 19–25. doi:10.1210/jc.2007-1809. PMID 17986639.
- ^ Athanasoulia-Kaspar AP, Stalla GK (2019). "Endokrinologische Betreuung von Patienten mit Transsexualität" [Endocrinological care of patients with transsexuality]. Geburtshilfe und Frauenheilkunde. 79 (7): 672–675. doi:10.1055/a-0801-3319. ISSN 0016-5751. S2CID 199033008.
- ^ Meriggiola MC, Gava G (November 2015). "Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen". Clinical Endocrinology. 83 (5): 607–615. doi:10.1111/cen.12754. PMID 25692882. S2CID 39706760.
- ^ Costa EM, Mendonca BB (March 2014). "Clinical management of transsexual subjects". Arquivos Brasileiros de Endocrinologia e Metabologia. 58 (2): 188–196. doi:10.1590/0004-2730000003091. PMID 24830596.
- ^ Moore E, Wisniewski A, Dobs A (August 2003). "Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects". The Journal of Clinical Endocrinology and Metabolism. 88 (8): 3467–3473. doi:10.1210/jc.2002-021967. PMID 12915619.
- ^ Rosenthal SM (December 2014). "Approach to the patient: transgender youth: endocrine considerations". The Journal of Clinical Endocrinology and Metabolism. 99 (12): 4379–4389. doi:10.1210/jc.2014-1919. PMID 25140398.
- ^ Arver DS (2015). "Transsexualism, könsdysfori". Retrieved 2018-11-12.
- ^ Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H (February 2016). "Risk of hormonotherapy in transgender people: Literature review and data from the French Database of Pharmacovigilance". Annales d'Endocrinologie. 77 (1): 14–21. doi:10.1016/j.ando.2015.12.001. PMID 26830952.
- ^ Asscheman H, Gooren LJ (1993). "Hormone Treatment in Transsexuals". Journal of Psychology & Human Sexuality. 5 (4): 39–54. doi:10.1300/J056v05n04_03. ISSN 0890-7064. S2CID 144580633.
- ^ Levy A, Crown A, Reid R (October 2003). "Endocrine intervention for transsexuals". Clinical Endocrinology. 59 (4): 409–418. doi:10.1046/j.1365-2265.2003.01821.x. PMID 14510900. S2CID 24493388.
- ^ Mirone V (12 February 2015). Clinical Uro-Andrology. Springer. pp. 17–. ISBN 978-3-662-45018-5.
- ^ Lim HH, Jang YH, Choi GY, Lee JJ, Lee ES (January 2019). "Gender affirmative care of transgender people: a single center's experience in Korea". Obstetrics & Gynecology Science. 62 (1): 46–55. doi:10.5468/ogs.2019.62.1.46. PMC 6333764. PMID 30671393.
When we prescribed estradiol, we preferred sublingual estradiol valerate instead of the oral form for feminizing HT since prior researchers have reported the effectiveness of sublingual administration in maintaining high blood estradiol concentration and low E1/E2 ratio [13].
- ^ Israel GE (March 2001). Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts. Temple University Press. pp. 56–. ISBN 978-1-56639-852-7.
- ^ Majumder A, Chatterjee S, Maji D, Roychaudhuri S, Ghosh S, Selvan C, George B, Kalra P, Maisnam I, Sanyal D (2020). "IDEA Group Consensus Statement on Medical Management of Adult Gender Incongruent Individuals Seeking Gender Reaffirmation as Female". Indian Journal of Endocrinology and Metabolism. 24 (2): 128–135. doi:10.4103/ijem.IJEM_593_19. PMC 7333765. PMID 32699777. S2CID 218596936.
- ^ Reisman T, Goldstein Z (2018). "Case Report: Induced Lactation in a Transgender Woman". Transgender Health. 3 (1): 24–26. doi:10.1089/trgh.2017.0044. PMC 5779241. PMID 29372185.
- ^ Henderson A (2003). "Domperidone. Discovering new choices for lactating mothers". AWHONN Lifelines. 7 (1): 54–60. doi:10.1177/1091592303251726. PMID 12674062.
- ^ "Orilissa (elagolix) FDA Label" (PDF). 24 July 2018. Retrieved 31 July 2018.